Targeting BCL11B-mediated JAK2/STAT3 activation: A novel therapeutic strategy for Parkinson’s disease
Abstract
Parkinson's disease (PD) is driven in part by neuroinflammation. We investigated whether the transcription factor BCL11B contributes to dopaminergic neurodegeneration in this context. Transcriptome sequencing of MPTP-induced PD mice revealed BCL11B upregulation, which was confirmed in MPP⁺-treated MN9D cells, MPTP-lesioned mice, and dopaminergic neurons exposed to inflammatory conditioned medium. BCL11B knockdown attenuated dopaminergic neuron loss, reduced apoptosis, improved motor deficits, and partially blocked JAK2/STAT3 pathway activation in both inflammatory and MPTP-induced PD models. Mechanistically, BCL11B mediated neurotoxicity through the JAK2/STAT3 pathway, with acetylation modifications potentially modulating its activity. These findings establish BCL11B as a key regulator of neuroinflammation and dopaminergic survival in PD, and suggest that targeting BCL11B may offer a therapeutic approach for this neurodegenerative disease.
Related
- Fecal Microbiota Transplantation: A Promising Therapeutic Strategy Targeting the Microbiota-Gut-Brain Axis in Anorexia Nervosa.
- NEURL1-mediated K63-ubiquitination of SLC40A1 drives ferroptosis resistance in pathological scars: Therapeutic targeting via autophagy-activating microneedles.
- Lipid droplet targeting drives substrate access during very long chain fatty acid activation by Fat1
- Exon Skipping as a Therapeutic Strategy Applied to an RYR1 Mutation with Pseudo-Exon Inclusion Causing a Severe Core Myopathy
- Therapeutic targeting of TCF/LEF transcription factors in neuropsychiatric disorders via Wnt/β-catenin signaling
BibTeX
@article{chen2026targeting,
title = {{Targeting BCL11B-mediated JAK2/STAT3 activation: A novel therapeutic strategy for Parkinson’s disease}},
author = {Wenwen Chen and Yejing Zhang and Xinrui Zhou and Jianan Yan and Yiming Song and Jiabing Shen and Xiaosu Gu},
journal = {iScience},
year = {2026},
month = oct,
doi = {10.1016/j.isci.2026.117833},
url = {https://www.cell.com/iscience/fulltext/S2589-0042(26)03214-1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Targeting BCL11B-mediated JAK2/STAT3 activation: A novel therapeutic strategy for Parkinson’s disease
AU - Wenwen Chen
AU - Yejing Zhang
AU - Xinrui Zhou
AU - Jianan Yan
AU - Yiming Song
AU - Jiabing Shen
AU - Xiaosu Gu
PY - 2026
DA - 2026/10/08
JO - iScience
DO - 10.1016/j.isci.2026.117833
UR - https://www.cell.com/iscience/fulltext/S2589-0042(26)03214-1
AB - Parkinson's disease (PD) is driven in part by neuroinflammation. We investigated whether the transcription factor BCL11B contributes to dopaminergic neurodegeneration in this context. Transcriptome sequencing of MPTP-induced PD mice revealed BCL11B upregulation, which was confirmed in MPP⁺-treated MN9D cells, MPTP-lesioned mice, and dopaminergic neurons exposed to inflammatory conditioned medium. BCL11B knockdown attenuated dopaminergic neuron loss, reduced apoptosis, improved motor deficits, and partially blocked JAK2/STAT3 pathway activation in both inflammatory and MPTP-induced PD models. Mechanistically, BCL11B mediated neurotoxicity through the JAK2/STAT3 pathway, with acetylation modifications potentially modulating its activity. These findings establish BCL11B as a key regulator of neuroinflammation and dopaminergic survival in PD, and suggest that targeting BCL11B may offer a therapeutic approach for this neurodegenerative disease.
SN - 2589-0042
ER -